The Rheumatologist
COVID-19 NewsACR Convergence
  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed
  • Home
  • Conditions
    • Rheumatoid Arthritis
    • SLE (Lupus)
    • Crystal Arthritis
      • Gout Resource Center
    • Spondyloarthritis
    • Osteoarthritis
    • Soft Tissue Pain
    • Scleroderma
    • Vasculitis
    • Systemic Inflammatory Syndromes
    • Guidelines
  • Resource Centers
    • Axial Spondyloarthritis Resource Center
    • Gout Resource Center
    • Psoriatic Arthritis Resource Center
    • Rheumatoid Arthritis Resource Center
    • Systemic Lupus Erythematosus Resource Center
  • Drug Updates
    • Biologics & Biosimilars
    • DMARDs & Immunosuppressives
    • Topical Drugs
    • Analgesics
    • Safety
    • Pharma Co. News
  • Professional Topics
    • Ethics
    • Legal
    • Legislation & Advocacy
    • Career Development
      • Certification
      • Education & Training
    • Awards
    • Profiles
    • President’s Perspective
    • Rheuminations
    • Interprofessional Perspective
  • Practice Management
    • Billing/Coding
    • Quality Assurance/Improvement
    • Workforce
    • Facility
    • Patient Perspective
    • Electronic Health Records
    • Apps
    • Information Technology
    • From the College
    • Multimedia
      • Audio
      • Video
  • Resources
    • Issue Archives
    • ACR Convergence
      • Gout Resource Center
      • Axial Spondyloarthritis Resource Center
      • Psoriatic Arthritis
      • Abstracts
      • Meeting Reports
      • ACR Convergence Home
    • American College of Rheumatology
    • ACR ExamRheum
    • Research Reviews
    • ACR Journals
      • Arthritis & Rheumatology
      • Arthritis Care & Research
      • ACR Open Rheumatology
    • Rheumatology Image Library
    • Treatment Guidelines
    • Rheumatology Research Foundation
    • Events
  • About Us
    • Mission/Vision
    • Meet the Authors
    • Meet the Editors
    • Contribute to The Rheumatologist
    • Subscription
    • Contact
  • Advertise
  • Search
You are here: Home / Articles / 3 New Study Summaries from AC&R: Obesity in RA, CPDD Risk Factors & SLE Disparities

3 New Study Summaries from AC&R: Obesity in RA, CPDD Risk Factors & SLE Disparities

August 14, 2022 • By Joshua F. Baker, MD, MSCE; Joel Kremer, MD; Jean Lieuw, MD, MS; Alfredo Aguirre, MD; & Jinoos Yazdany, MD, MPH

  • Tweet
  • Email
Print-Friendly Version / Save PDF

You Might Also Like
  • New Study Examines Pregnancy Risk Factors for Patients with Lupus
  • Comorbidities & Risk Factors for Developing SLE
  • Recent Research: Study Summaries from Arthritis Care & Research
Explore This Issue
August 2022

1) Obesity & Treatment Response in RA

Obesity & response to advanced therapies in rheumatoid arthritis

Why was this study done? There have been questions regarding whether certain therapies for rheumatoid arthritis (RA) are less effective in patients with obesity, particularly for tumor necrosis factor (TNF) inhibitors, because adipose tissue is known to generate TNF, among other inflammatory mediators.

ad goes here:advert-1
ADVERTISEMENT
SCROLL TO CONTINUE

What were the study methods? We studied 5,901 patients enrolled in the CorEvitas registry who were initiating a TNF inhibitor or a non-TNF inhibitor biologic. We used linear and logistic regression to look at response to therapy across a range of body mass indexes (BMI). We first looked at response to any therapy, then tested to see whether any observed effect of obesity on response differed between those initiating a TNF inhibitor and those initiating a non-TNF biologic. We adjusted analyses for potential confounding factors, such as age, disease activity and comorbidities.

What were the key findings? There were three main observations. First, obesity was associated with a reduced response to therapy, although the effect was modest after adjustment. Specifically, patients with obesity had modestly lower odds of achieving low disease activity six months after starting a biologic therapy (odds ratio [OR]=0.88).

ad goes here:advert-2
ADVERTISEMENT
SCROLL TO CONTINUE

Second, there was no difference in this effect whether the person received a TNF inhibitor therapy or a non-TNF inhibitor therapy, suggesting the lack of response in this group was not treatment specific.

Third, underweight patients were much less likely to respond to both types of therapies (OR=0.32) even after adjustment. With regard to these observations, it didn’t seem to matter whether the medication used weight-based dosing.

What were the main conclusions? Although obese and underweight patients may indeed show lower responses to therapy, this is not therapy specific.

ad goes here:advert-3
ADVERTISEMENT
SCROLL TO CONTINUE

What are the implications for patients? When starting therapy, underweight and obese patients should recognize the treatment may not be as effective for them as for others—although it’s not clear the treatment strategy should be different.

What are the implications for clinicians? The impact of obesity on health is broad, which may explain why lower clinical responses are observed for multiple types of therapies with different mechanisms of action. Obesity may cause persistent symptoms of obesity-related conditions (e.g., osteoarthritis, fibromyalgia) and promote systemic inflammation through release of cytokines and adipocytokines. Underweight patients may have experienced cachexia due to a high burden of systemic inflammation; this may explain the lower responses observed in this group.

Pages: 1 2 3 4 | Single Page

Filed Under: Conditions, Research Reviews, Rheumatoid Arthritis, SLE (Lupus) Tagged With: Arthritis Care & Research, calcium pyrophosphate deposition disease, Disparities, Obesity, Reading RheumIssue: August 2022

You Might Also Like:
  • New Study Examines Pregnancy Risk Factors for Patients with Lupus
  • Comorbidities & Risk Factors for Developing SLE
  • Recent Research: Study Summaries from Arthritis Care & Research
  • Racial Disparities Result in Unprecedented Differences in Outcomes for SLE Patients

American College of Rheumatology

Visit the official website for the American College of Rheumatology.

Visit the ACR »

ACR Convergence

Don’t miss rheumatology’s premier scientific meeting for anyone involved in research or the delivery of rheumatologic care or services.

Visit the ACR Convergence site »

Rheumatology Research Foundation

The Foundation is the largest private funding source for rheumatology research and training in the U.S.

Learn more »

The Rheumatologist newsmagazine reports on issues and trends in the management and treatment of rheumatic diseases. The Rheumatologist reaches 11,500 rheumatologists, internists, orthopedic surgeons, nurse practitioners, physician assistants, nurses, and other healthcare professionals who practice, research, or teach in the field of rheumatology.

About Us / Contact Us / Advertise / Privacy Policy / Terms of Use / Cookie Preferences

  • Connect with us:
  • Facebook
  • Twitter
  • LinkedIn
  • YouTube
  • Feed

Copyright © 2006–2023 American College of Rheumatology. All rights reserved.

ISSN 1931-3268 (print)
ISSN 1931-3209 (online)